Edit
Ophthalmology Innovation Source
https://ois.net/encore-vision-delivers-big-payday-to-angel-investors/Last activity: 12.11.2024
Active
The Ophthalmology Innovation Summits facilitate meaningful interactions and the exchange of information between clinical, capital and corporate leaders to accelerate the development and commercialization of novel therapies to address unmet needs.
The Ophthalmology Innovation Summit (OIS) was conceptualized and developed by ophthalmologist/venture capitalist Emmett Cunningham of Clarus Funds now Blackstone Life Sciences. To make his vision for OIS a reality, Emmett enrolled legendary venture capitalists, Bill Link of Versant Ventures/Flying L Partners to Co-Chair the summits. The addition of experienced conference producer, Craig Simak brought the event to life in 2009. Since then, the OIS franchise has expanded to precede several ophthalmic and optometric societies and unites thousands of industry and clinical leaders each year.
The Ophthalmology Innovation Summit (OIS) was conceptualized and developed by ophthalmologist/venture capitalist Emmett Cunningham of Clarus Funds now Blackstone Life Sciences. To make his vision for OIS a reality, Emmett enrolled legendary venture capitalists, Bill Link of Versant Ventures/Flying L Partners to Co-Chair the summits. The addition of experienced conference producer, Craig Simak brought the event to life in 2009. Since then, the OIS franchise has expanded to precede several ophthalmic and optometric societies and unites thousands of industry and clinical leaders each year.
Location: United States, New York, Jericho
Employees: 11-50
Founded date: 2009
Investors 1
| Date | Name | Website |
| - | Cowtown An... | cowtownang... |
Mentions in press and media 17
| Date | Title | Description |
| 12.11.2024 | Opthea’s Wet AMD Program Featured at Ophthalmology Events | 17 Congress of the Asia-Pacific Vitreo-Retina Society, November 22 - 24, 2024 Ophthalmology Innovation Summit XIV, November 23, 2024 MELBOURNE, Australia, and PRINCETON, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OP... |
| 14.12.2022 | Annexin receives Innovation Award at an international conference | Annexin receives Innovation Award at an international conference Wed, Dec 14, 2022 09:00 CET Report this content STOCKHOLM December 14, 2022 Annexin Pharmaceuticals AB (Publ) ("Annexin" or "the Company") announces today ... |
| 21.11.2022 | Ocuphire to Present at Five Upcoming Investor/Industry Conferences | /EIN News/ -- FARMINGTON HILLS, Mich., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of re... |
| 19.01.2022 | onward! onl hits milestones and achieves tranche 2 funding OF $46.9 MILLION SERIES B | Congratulations to the ONL team on reaching significant milestones in 2021. This tranche of funding will further expand three programs and move ONL1204 closer to the clinic. We'd like to thank and congratulate Mr. Esposito, Dr. Zacks, and... |
| 27.12.2021 | OIS Year in review | Dr. Rahhal sits down with Craig Simak, OIS co-founder, and fellow OIS podcast hosts, Robert Rothman, MD (InFocus Capital Partners) and Ehsan Sadri, MD, FACS (Visionary Ventures) to discuss the OIS 2021 Year in Review: Shrugging Off the Pand... |
| 17.03.2021 | Hovione completes its Phase 2 clinical trial of the first minocycline ophthalmic showing promise in Dry Eye Disease associated with Inflamed Meibomian Gland Dysfunction | CORK, Ireland, March 17, 2021 /PRNewswire/ -- Hovione announced at the Ophthalmology Innovation Summit (OIS) Dry Eye Showcase the successful completion of its Phase 2 clinical trial in 270 patients with Dry Eye caused by Meibomian Gland Dys... |
| 06.01.2021 | Silver Linings: ExSight's 2020 year in review | The below is taken from an update we shared with our investors, portfolio companies, and friends as 2020 came to a close. We share some of these reflections here as well. We're hopeful and optimistic that 2021 will bring much more positivit... |
| 22.12.2020 | Rolling on: ONL Therapeutics closes $46.9 million Series B financing | Beyond retinal detachment, lead candidate ONL1204 will also advance into the chronic conditions of glaucoma and dry age-related macular degeneration ONL Therapeutics, Inc. (“ONL”), a clinical-stage biopharmaceutical company and ExSight Ven... |
| 06.10.2020 | Re-vana Therapeutics delivers $3.2 Million oversubscribed round | ExSight Ventures ("ExSight") is pleased to announce our investment Re-Vana Therapeutics, Ltd, ("Re-Vana") to support pre-clinical development of sustained-release biologic and small molecule therapeutics. ExSight is prou... |
| 28.08.2020 | Podcast potpourri | Dr. Rahhal is quickly becoming a prolific podcaster. In this week's roundup Firas hosts three podcasts with another impressive list of guests offering different perspectives on ophthalmic innovation. In this third OIS Retina Podcast, host ... |
Show more